SCHEMBL6430910

SCHEMBL6430910

NC(=O)c1cccc(NC(=O)Nc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.70
KMT2A Q03164 4/20 0.70
HTT P42858 3/20 0.70
MEN1 O00255 2/20 0.70
RAB9A P51151 1/20 0.70
ALDH1A1 P00352 3/20 0.68
KCNMA1 Q12791 1/20 0.63
CA12 O43570 1/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
CA9 Q16790 1/20 0.63
TP53 P04637 1/20 0.59
GAA P10253 1/20 0.59
KDR P35968 1/20 0.59
LMNA P02545 2/20 0.58
PKM P14618 1/20 0.58
AURKA O14965 1/20 0.58
GRIK1 P39086 2/20 0.58
PTGS1 P23219 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13568446 0.89 MAPT (0.67) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL5597699 0.87 KMT2A (0.90) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL30101230 0.87 KMT2A (0.90) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL4476633 0.87 MAPT (0.86) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL31060524 0.87 MAPT (0.76) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL4462072 0.87 MAPT (0.76) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL6431565 0.87 MAPT (0.77) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL4548162 0.86 KMT2A (0.87) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL27942776 0.85 MAPT (0.63) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL17664317 0.83 KMT2A (0.81) MAPTKMT2AHTTMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity POSEIDON PHARMACEUTICALS A/S (DK) 2005-04-14 US claimed
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity POSEIDON PHARMACEUTICALS A/S (DK) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity CPA3, HNMT, CMA1 MAPT 1603/4885KMT2A 1345/4885HTT 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.